The UC Davis Health System Eye Center is hosting a reception for study participants to celebrate the completion of the landmark Ocular Hypertension Treatment Study, a nationwide, multi-center clinical trial that found that the daily use of pressure-lowering eyedrops can delay or even prevent the onset of open-angle glaucoma, one of the leading causes of blindness.
Saturday, Sept. 20, from 4 to 6 p.m.
Robert Matsui Lecture Hall
4610 X St., Sacramento
Nearly half of the 116 study participants from Sacramento and as far away as Portland, Ore., will attend the event. Among the subjects will be Michael Gallagher, who enrolled after a routine physical found that he had elevated pressure inside his eyes and was at risk for glaucoma. Today, after 15 years of participation in the study, Gallagher shows no signs of the disease.
Launched in 1994, the Ocular Hypertension Treatment Study examined 1,636 people 40 to 80 years of age. The study resulted in the publication of 30 research papers, the development of a validated prediction model for glaucoma and conclusive proof that daily use of pressure-lowering eyedrops can delay or prevent the disease.